HC Wainwright Predicts Higher Earnings for Benitec Biopharma

Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) - Equities research analysts at HC Wainwright increased their FY2025 earnings per share estimates for shares of Benitec Biopharma in a note issued to investors on Monday, May 19th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will earn ($1.33) per share for the year, up from their prior estimate of ($1.55). HC Wainwright currently has a "Buy" rating and a $28.00 target price on the stock. The consensus estimate for Benitec Biopharma's current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Benitec Biopharma's Q4 2025 earnings at ($0.25) EPS.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last issued its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.12.

Separately, JMP Securities reissued a "market outperform" rating and issued a $20.00 price objective on shares of Benitec Biopharma in a research note on Thursday, May 15th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $24.71.

Benitec Biopharma Stock Performance

BNTC stock traded down $0.40 during trading on Wednesday, reaching $13.19. 36,388 shares of the company were exchanged, compared to its average volume of 41,273. The stock's 50 day moving average price is $13.54 and its 200 day moving average price is $12.14. Benitec Biopharma has a 52-week low of $5.74 and a 52-week high of $16.90. The company has a market cap of $337.66 million, a P/E ratio of -8.74 and a beta of 0.34.

Institutional Investors Weigh In On Benitec Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Suvretta Capital Management LLC raised its holdings in Benitec Biopharma by 1.5% in the fourth quarter. Suvretta Capital Management LLC now owns 8,960,009 shares of the biotechnology company's stock valued at $113,165,000 after buying an additional 130,956 shares during the period. Franklin Resources Inc. increased its holdings in Benitec Biopharma by 269.0% in the 4th quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company's stock valued at $37,123,000 after purchasing an additional 2,142,643 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Benitec Biopharma by 198.5% in the 4th quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company's stock valued at $33,268,000 after purchasing an additional 1,739,904 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in Benitec Biopharma by 134.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company's stock valued at $24,913,000 after purchasing an additional 1,131,129 shares during the period. Finally, Infinitum Asset Management LLC lifted its stake in shares of Benitec Biopharma by 435.7% during the first quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company's stock worth $14,636,000 after purchasing an additional 915,000 shares in the last quarter. 52.19% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Benitec Biopharma

In other news, Director Suvretta Capital Management, L bought 900,000 shares of Benitec Biopharma stock in a transaction that occurred on Wednesday, March 26th. The shares were purchased at an average price of $13.00 per share, for a total transaction of $11,700,000.00. Following the completion of the acquisition, the director now owns 8,793,245 shares of the company's stock, valued at $114,312,185. The trade was a 11.40% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.30% of the company's stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.